We are live on ! Find out more
UTHR icon

United Therapeutics

850 hedge funds and large institutions have $24.6B invested in United Therapeutics in 2026 Q1 according to their latest regulatory filings, with 111 funds opening new positions, 300 increasing their positions, 322 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more funds holding in top 10

Funds holding in top 10: 1626 (+10)

34% more first-time investments, than exits

New positions opened: 111 | Existing positions closed: 83

21% more capital invested

Capital invested by funds: $20.3B → $24.6B (+$4.28B)

2% more funds holding

Funds holding: 837850 (+13)

4% more call options, than puts

Call options by funds: $1.21B | Put options by funds: $1.17B

7% less repeat investments, than reductions

Existing positions increased: 300 | Existing positions reduced: 322

2.23% less ownership

Funds ownership: 96.94%94.71% (-2.2%)

Holders
850
Holders Change
+13
Holders Change %
+1.55%
% of All Funds
10.46%
Holding in Top 10
26
Holding in Top 10 Change
+10
Holding in Top 10 Change %
+62.5%
% of All Funds
0.32%
New
111
Increased
300
Reduced
322
Closed
83
Calls
$1.21B
Puts
$1.17B
Net Calls
+$43M
Net Calls Change
+$4.64M

UTHR Hedge Fund Activity: Q1 2026 in Review

850 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2026, worth a combined $24.6B — up 21% from $20.3B a quarter earlier.

Buyers outnumbered sellers: 111 funds opened new UTHR positions and 83 closed out — a net gain of 28 holders — while 300 added to existing stakes and 322 trimmed.

The largest buyer was BlackRock, adding an estimated $114M. The largest seller was AQR Capital Management, cutting an estimated $227M.

  • 850 institutional investors held United Therapeutics (UTHR) as of Q1 2026, up from 837 in Q4 2025.
  • Funds reported $24.6B of United Therapeutics stock for Q1 2026, up 21% quarter-over-quarter.
  • 111 funds opened new United Therapeutics positions in Q1 2026 and 83 closed out, a net change of +28 holders.
  • The largest United Therapeutics buyer in Q1 2026 was BlackRock, an estimated $114M added.
  • The largest United Therapeutics seller in Q1 2026 was AQR Capital Management, an estimated $227M sold.

Based on aggregated 13F filings for Q1 2026.